Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0001175 (
AIDS
)
120,706
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
A high frequency of lymphoma in human immunodeficiency virus-infected individuals has been reported since the outbreak of the
acquired immunodeficiency syndrome
(
AIDS
) epidemic in 1982.
AIDS
-associated non-Hodgkin's lymphoma (AIDS-NHL) is almost invariably derived from B cells and is classified as high- or intermediate-grade NHL, according to the working formulation. Two main histologic types are recognized, including small noncleaved cell lymphoma (SNCCL) and diffuse large cell lymphoma (DLCL). Pre-existing host factors putatively involved in lymphoma development include disrupted immunosurveillance, deregulated cytokine production, chronic antigen stimulation, and infection by Epstein-Barr virus (EBV). These alterations are associated with the development of multiple oligoclonal expansions which correspond to the clinical phase known as persistent generalized lymphadenopathy (PGL). The appearance of a true
AIDS
-NHL is characterized by the presence of a monoclonal B-cell population displaying several genetic lesions, including monoclonal EBV infection, c-MYC and
BCL-6
rearrangements, RAS mutations, p53 inactivation, and 6q deletions. These genetic lesions cluster into two distinct molecular pathways, which specifically associate with the different histologic subtypes of
AIDS
-NHL, i.e.,
AIDS
-SNCCL and
AIDS
-DLCL. The presence of distinct genetic pathways for
AIDS
-SNCCL and
AIDS
-DLCL correlate with a number of clinical features which distinguish these two groups of tumors, including differences in the age of onset, CD4 counts at the time of presentation, time elapsed since HIV infection, and clinical outcome.
...
PMID:Molecular pathology of AIDS-related lymphomas. Biologic aspects and clinicopathologic heterogeneity. 799 35
Acquired immunodeficiency syndrome
(
AIDS
)-associated non-Hodgkin's lymphomas (
AIDS
-NHL), a major source of morbidity and mortality among
AIDS
patients, are derived from B cells and can be classified into two main histologic categories, small noncleaved cell lymphoma (SNCCL) and diffuse large-cell lymphoma (DLCL). DLCL includes two histologic subsets, ie, large noncleaved cell lymphoma (LNCCL) and large cell-immunoblastic plasmacytoid lymphoma (LC-IBPL). Several studies have shown that
AIDS
-SNCCL is associated with the clonal accumulation of multiple genetic lesions, including Epstein-Barr virus (EBV) infection, activation of the c-MYC and RAS oncogenes, as well as inactivation of the p53 tumor suppressor gene at variable frequencies. On the contrary, the molecular pathogenesis of
AIDS
-DLCL is largely obscure, because no genetic lesion other than EBV infection has been specifically identified in this group. In this study, we have tested a panel of 40
AIDS
-NHL for structural alterations of
BCL-6
, a putative proto-oncogene that is frequently altered in DLCL in the immunocompetent host. Our results show that rearrangements of
BCL-6
are present in 20% of
AIDS
-DLCL (5 of 24), including 2 of 8 LNCCL and 3 of 16 LC-IBPL, but in no case of
AIDS
-SNCCL.
BCL-6
rearrangements were detected both in the presence and in the absence of EBV infection of the tumor clone, but in no case were associated with activation of c-MYC or mutations of p53. These data identify a novel genetic lesion in
AIDS
-DLCL and corroborate the notion that lymphomagenesis in
AIDS
follows two distinct molecular pathways that are associated with the development of histologically distinct types of
AIDS
-NHL.
...
PMID:Rearrangements of the BCL-6 gene in acquired immunodeficiency syndrome-associated non-Hodgkin's lymphoma: association with diffuse large-cell subtype. 802 68
AIDS
-related non-Hodgkin lymphomas (AIDS-NHL) are most frequently derived from B cells and include small non-cleaved cell lymphoma (SNCCL) and diffuse large cell lymphoma (DLCL) and less frequently anaplastic large cell lymphoma (ALCL) or body cavity-based lymphoma (BCBL).
AIDS
-NHL cell lines have proved useful to study
AIDS
-NHL pathogenesis. In this report, we describe the establishment and molecular characterization of two novel
AIDS
-NHL cell lines (HBL-4 and HBL-6) derived from lymphomatous effusions. HBL-4 was derived from a patient with SNCCL, whereas HBL-6 was derived from a patient with BCBL. The identity of the cell lines with the original tumor clone was established by immunoglobulin gene rearrangement analysis. Both HBL-4 and HBL-6 carry a monoclonal EBV infection and do not contain HIV. In addition, HBL-6 harbors DNA sequences of the recently identified Kaposi's sarcoma-associated herpesvirus (KSHV), now formally called human herpesvirus 8 (HHV8). Finally, HBL-4, but not HBL-6, harbors a rearranged c-MYC allele, while the
BCL-6
gene displayed a germline configurations in both cell lines. These
AIDS
-NHL cell lines may prove useful in understanding the biologic events contributing to
AIDS
-NHL development.
...
PMID:Establishment of AIDS-related lymphoma cell lines from lymphomatous effusions. 868 8
This study aimed at investigating the expression of the
BCL-6
protein in
acquired immune deficiency syndrome
(
AIDS
)-related non-Hodgkin's lymphomas (AIDS-NHLs) and at comparing the expression pattern with the presence of Epstein-Barr virus (EBV) infection of the tumor clone. A total of 34
AIDS
-NHL biopsies, including 16
AIDS
-related diffuse large-cell lymphomas (AIDS-DLCLs) and 18
AIDS
-related small-noncleaved-cell lymphomas (AIDS-SNCCLs) as well as 7
AIDS
-SNCCL cell lines were immunostained with a
BCL-6
-specific monoclonal antibody. Expression of
BCL-6
protein was detected in 9 of 16
AIDS
-DLCLs, 18 of 18
AIDS
-SNCCLs, and 3 of 7
AIDS
-SNCCL cell lines. Expression of
BCL-6
among
AIDS
-NHLs occurred independently of the presence of molecular lesions of the bcl-6 gene. Notably, among EBV-positive
AIDS
-NHL biopsies and cell lines, expression of
BCL-6
was mutually exclusive with the expression of EBV-encoded transforming antigen latent membrane protein-1. The mutual exclusion between
BCL-6
and latent membrane protein-1 expression was further confirmed by in vitro superinfection experiments of an
AIDS
-SNCCL cell line originally devoid of EBV sequences. Overall, the frequent association between
AIDS
-NHLs and expression of
BCL-6
, a protein selectively expressed by germinal center B cells, suggests that these lymphomas may originate from the germinal center.
...
PMID:BCL-6 protein expression in AIDS-related non-Hodgkin's lymphomas: inverse relationship with Epstein-Barr virus-encoded latent membrane protein-1 expression. 900 32
Acquired immunodeficiency syndrome
(
AIDS
)-related non-Hodgkin's lymphomas (
AIDS
-NHL), a major source of morbidity and mortality among human immunodeficiency virus (HIV)-infected individuals, are derived from B cells and are classified into two major categories, Burkitt's lymphoma (BL) and diffuse large cell lymphoma (DLCL). Anaplastic large cell lymphoma (ALCL) and body-cavity-based lymphoma (BCBL) represent less frequent
AIDS
-NHL types. The molecular pathogenesis of
AIDS
-NHL is characterized by distinct genetic pathways, including chromosomal rearrangements of c-MYC and
BCL-6
in
AIDS
-BL and
AIDS
-DLCL, respectively. In addition to gross rearrangements, recent evidence has suggested that
BCL-6
may also be affected by mutations of the gene 5' noncoding regions. Here we have investigated the distribution of
BCL-6
mutations in a panel representative of all the
AIDS
-NHL subtypes. Forty-three
AIDS
-NHL were analyzed for mutations in the first exon-first intron boundary region of
BCL-6
. Mutations were detected in all categories of
AIDS
-NHL (25 of 43 cases; 58%), including 12 of 20
AIDS
-BL, 10 of 15
AIDS
-DLCL, two of three
AIDS
-ALCL, and one of five of
AIDS
-BCBL.
BCL-6
mutations occurred independent of
BCL-6
rearrangements and presence of other genetic lesions frequently associated with
AIDS
-NHL. These results indicate that mutations of BCL-65' noncoding regions represent the most common genetic alteration presently detectable in
AIDS
-NHL. The frequency of these mutations, as well as their location in the proximity of
BCL-6
regulatory sequences, suggest that they may play a role in
AIDS
-related lymphomagenesis.
...
PMID:Frequent mutation of the 5' noncoding region of the BCL-6 gene in acquired immunodeficiency syndrome-related non-Hodgkin's lymphomas. 916 Jun 81
AIDS-related small noncleaved cell lymphoma (AIDS-SNCCL) includes Burkitt's lymphoma (BL) and high-grade B-cell Burkitt-like lymphoma (BLL). Due to the marked polymorphism of
AIDS
-related non-Hodgkin's lymphomas (AIDS-NHL), the morphologic distinction between these two types of lymphomas is frequently controversial, although it may bear clinical relevance. Although the molecular features of
AIDS
-BL have been clarified to a certain extent, the genetic peculiarities of
AIDS
-BLL have not been investigated in detail. In this study we have compared morphologic and genetic features of
AIDS
-BL and
AIDS
-BLL in a blind coded fashion. Molecular studies were focused on the genetic lesions known to be implicated in
AIDS
-NHL, including alterations of c-MYC,
BCL-6
, p53, deletions of 6q, as well as infection by EBV and HHV-8. Alterations of c-MYC occurred in 10/10
AIDS
-BL, whereas they were restricted to 2/10
AIDS
-BLL (P < 0.01). Mutations of p53 were present in 5/10
AIDS
-BL, whereas they were consistently absent among
AIDS
-BLL (n = 10; P < 0.05). Infection by EBV occurred in 30% of both
AIDS
-BL and
AIDS
-BLL. Rearrangements of
BCL-6
, deletions of 6q and infection by HHV-8 scored consistently negative in both
AIDS
-BL and
AIDS
-BLL. Based on the genetic lesions tested, the molecular profile of
AIDS
-BLL appears to be closer to that of AIDS-related diffuse large cell lymphoma (AIDS-DLCL) than to that of
AIDS
-BL. In contrast to
AIDS
-BLL however,
AIDS
-DLCL carried rearrangements of
BCL-6
in a fraction of cases (2/9). This study, the largest of its kind reported so far, suggests that
AIDS
-BL and
AIDS
-BLL have a different molecular pathogenesis and that characterization of genetic lesions may help to distinguish between these two lymphomas.
...
PMID:Genetic heterogeneity of AIDS-related small non-cleaved cell lymphoma. 933 31
This study was aimed at defining the histogenesis of the pathologic spectrum of
acquired immunodeficiency syndrome
-related non-Hodgkin's lymphomas (AIDS-NHL), including AIDS-related small noncleaved cell lymphoma (AIDS-SNCCL),
AIDS
-related large noncleaved cell lymphoma (AIDS-LNCCL),
AIDS
-related large cell immunoblastic lymphoma plasmacytoid (AIDS-IBLP), and
AIDS
-related primary effusion lymphoma (AIDS-PEL). Forty-six cases of
AIDS
-NHL were investigated for the expression pattern of
BCL-6
, a protein specifically expressed by germinal center (GC) B-cells, and CD138/syndecan-1 (syn-1), a marker of post-GC B-cell differentiation. Expression of
BCL-6
and syn-1 segregated two major phenotypic patterns among
AIDS
-NHL: (1) the BCL-6+/syn-1- pattern associated with
AIDS
-SNCCL and
AIDS
-LNCCL; (2) the
BCL-6
-/syn-1+ pattern associated with
AIDS
-IBLP and
AIDS
-PEL. Among systemic
AIDS
-NHL infected by Epstein-Barr virus (EBV), expression of the EBV-encoded latent membrane protein-1 (LMP-1) preferentially associated with the
BCL-6
-/syn-1+ profile. Analysis of nonneoplastic lymph nodes showed that the two phenotypic patterns detected in
AIDS
-NHL correspond to physiologic stages of B-cell development, i.e., GC B-cells (BCL-6+/syn-1-) and preterminally differentiated post-GC B-cells (
BCL-6
-/syn-1+). Thus, BCL-6+/syn-1-
AIDS
-NHL reflects a GC stage of differentiation, whereas
AIDS
-NHL which are
BCL-6
-/syn-1+, and LMP-1+ when infected by EBV, derive from B cells that have entered post-GC plasmacell differentiation. These findings are relevant for the pathogenesis and differential diagnosis of
AIDS
-NHL.
...
PMID:Differential expression of BCL-6, CD138/syndecan-1, and Epstein-Barr virus-encoded latent membrane protein-1 identifies distinct histogenetic subsets of acquired immunodeficiency syndrome-related non-Hodgkin's lymphomas. 944 32
Primary central nervous system lymphoma (PCNSL) is a major cause of morbidity and mortality among human immunodeficiency virus (HIV)-infected individuals. The precise histogenetic derivation and the molecular pathogenesis of PCNSL is poorly understood. In an attempt to clarify the histogenesis and pathogenesis of these lymphomas, 49 PCNSL (26
acquired immunodeficiency syndrome
[
AIDS
]-related and 23
AIDS
-unrelated) were analyzed for multiple biologic markers, which are known to bear histogenetic and pathogenetic significance for mature B-cell neoplasms. PCNSL associated frequently (50.0%) with mutations of
BCL-6
5' noncoding regions, which are regarded as a marker of B-cell transition through the germinal center (GC). Expression of
BCL-6
protein, which is restricted to GC B cells throughout physiologic B-cell maturation, was detected in 100%
AIDS
-unrelated PCNSL and in 56.2%
AIDS
-related cases. Notably, among
AIDS
-related PCNSL, expression of
BCL-6
was mutually exclusive with expression of Epstein-Barr virus (EBV)-encoded latent membrane protein (LMP)-1 and, with few exceptions, also of BCL-2. All but one PCNSL expressed hMSH2, which among mature B cells selectively stains GC B cells. These data suggest that PCNSL may be frequently related to GC B cells and may be segregated into two major biologic categories based on the expression pattern of
BCL-6
, LMP-1, and BCL-2.
BCL-6
(+)/LMP-1(-)/BCL-2(-) PCNSL occur both in the presence and in the absence of HIV infection and consistently display a large noncleaved cell morphology. Conversely,
BCL-6
(-)/LMP-1(+)/BCL-2(+) PCNSL are restricted to HIV-infected hosts and are represented by lymphomas with immunoblastic features. These data are relevant for the pathogenesis and histogenesis of PCNSL and may be helpful to segregate distinct biologic and prognostic categories of these lymphomas.
...
PMID:The molecular and phenotypic profile of primary central nervous system lymphoma identifies distinct categories of the disease and is consistent with histogenetic derivation from germinal center-related B cells. 968 Mar 71
The molecular pathogenesis of systemic
acquired immunodeficiency syndrome
(
AIDS
)-related non-Hodgkin's lymphomas (
AIDS
-NHL) is a complex process involving both host factors and the accumulation of genetic lesions within the tumor clone. On the basis of the pattern of molecular lesions involved in these tumors, several distinct pathogenetic pathways can be presently identified in
AIDS
-related lymphomagenesis. These pathways selectively associate with the different clinicopathologic variants of
AIDS
-NHL.
AIDS
-related Burkitt's lymphoma is characterized by activation of c-MYC in all cases, disruption of p53 in 60% of the cases, and infection by Epstein-Barr virus (EBV) in 30% of the cases.
AIDS
-related diffuse large-cell lymphoma harbor frequent EBV infection (80%) and, in 20% of the cases,
BCL-6
rearrangements. Finally, the pathogenesis of
AIDS
-related body cavity-based lymphoma involves infection by human herpesvirus-8 in all cases and frequently also the co-infection by EBV.
...
PMID:Genetic basis of acquired immunodeficiency syndrome-related lymphomagenesis. 970 10
AIDS
-related non-Hodgkin's lymphomas (AIDS-NHL) are classified into Burkitt's lymphoma, diffuse large cell lymphoma (DLCL), and body cavity based lymphoma. The molecular pathogenesis of
AIDS
-NHL is complex and involves the genetic alteration of several cancer related genes, including the
BCL-6
proto-oncogene.
BCL-6
encodes a zinc finger transcription factor which is selectively expressed by germinal center (GC) B-cells, but not by pre-GC or post-GC B-cells. Genetic alterations of
BCL-6
occur frequently among B-cell NHL and comprise gross rearrangements as well as small mutations of the 5' noncoding region of the gene. Gross rearrangements of
BCL-6
among
AIDS
-NHL cluster with 20%
AIDS
-DLCL. Conversely, mutations of the 5' noncoding region of
BCL-6
occur at sustained frequency throughout the clinico-pathologic spectrum of
AIDS
-NHL and represent the most common genetic alteration presently detectable in these lymphomas. The frequency of
BCL-6
mutations, as well as their location in the proximity of the
BCL-6
regulatory regions, suggest that they may play a pathogenetic role in
AIDS
-related lymphomagenesis. Beside their pathogenetic implications, the occurrence of
BCL-6
mutations among
AIDS
-NHL bears histogenetic relevance because
BCL-6
mutations are regarded as a marker of B-cell transition through the GC. Thus, it is conceivable that a large fraction of
AIDS
-NHL is histogenetically related to GC or post-GC B-cells. This notion is further confirmed by the observation that
AIDS
-NHL frequently express the
BCL-6
protein, which stains selectively GC B-cells throughout B-cell differentiation.
...
PMID:BCL-6 in aids-related lymphomas: pathogenetic and histogenetic implications. 972 Jul 13
1
2
3
Next >>